| Primary |
| Renal Cell Carcinoma |
28.9% |
| Prophylaxis |
19.1% |
| Hypertension |
9.7% |
| Metastatic Renal Cell Carcinoma |
9.0% |
| Mantle Cell Lymphoma |
4.1% |
| Premedication |
3.5% |
| Pain |
3.4% |
| Diabetes Mellitus |
3.0% |
| Nausea |
2.4% |
| Constipation |
2.0% |
| Multiple Myeloma |
2.0% |
| Renal Cancer |
1.8% |
| Insomnia |
1.6% |
| Renal Cancer Metastatic |
1.6% |
| B Precursor Type Acute Leukaemia |
1.3% |
| Pyrexia |
1.3% |
| Vomiting |
1.3% |
| Depression |
1.3% |
| Neoplasm |
1.2% |
| Prostate Cancer |
1.2% |
|
| Death |
10.0% |
| Disease Progression |
8.6% |
| Renal Cell Carcinoma |
7.2% |
| Vomiting |
7.2% |
| Pneumonia |
6.0% |
| Sepsis |
6.0% |
| Pleural Effusion |
5.8% |
| Febrile Neutropenia |
4.8% |
| Pneumocystis Jiroveci Pneumonia |
4.6% |
| Stomatitis |
4.4% |
| Thrombocytopenia |
4.2% |
| Dyspnoea |
4.0% |
| Respiratory Failure |
4.0% |
| Dehydration |
3.6% |
| Sudden Death |
3.6% |
| Proteinuria |
3.4% |
| Interstitial Lung Disease |
3.2% |
| Nephrotic Syndrome |
3.2% |
| Pyrexia |
3.2% |
| Hyperkalaemia |
3.0% |
|
| Secondary |
| Renal Cell Carcinoma |
26.7% |
| Drug Use For Unknown Indication |
17.8% |
| Prophylaxis |
13.1% |
| Metastatic Renal Cell Carcinoma |
8.0% |
| Hypertension |
5.6% |
| Pain |
4.6% |
| Mantle Cell Lymphoma |
4.1% |
| Renal Cancer |
3.2% |
| Diabetes Mellitus |
1.9% |
| Nausea |
1.8% |
| Product Used For Unknown Indication |
1.7% |
| Endometrial Cancer |
1.7% |
| Head And Neck Cancer |
1.7% |
| Premedication |
1.4% |
| Upper Respiratory Tract Infection |
1.2% |
| Lymphoma |
1.2% |
| Neoplasm |
1.1% |
| Mantle Cell Lymphoma Refractory |
1.1% |
| Constipation |
1.1% |
| Hypercholesterolaemia |
1.1% |
|
| Renal Cell Carcinoma |
8.5% |
| Vomiting |
7.6% |
| Death |
7.4% |
| Pneumonia |
6.5% |
| Sinusitis |
6.2% |
| Interstitial Lung Disease |
5.6% |
| Pleural Effusion |
5.6% |
| Pyrexia |
5.4% |
| Pulmonary Embolism |
4.7% |
| Anaemia |
4.5% |
| Sepsis |
4.4% |
| Thrombocytopenia |
4.4% |
| Diarrhoea |
4.2% |
| Stomatitis |
4.0% |
| Dehydration |
3.6% |
| Disease Progression |
3.6% |
| Renal Failure |
3.6% |
| Hyperkalaemia |
3.4% |
| Dyspnoea |
3.3% |
| Vision Blurred |
3.3% |
|
| Concomitant |
| Mantle Cell Lymphoma |
19.5% |
| Pain |
13.9% |
| Product Used For Unknown Indication |
12.0% |
| Metastatic Renal Cell Carcinoma |
9.8% |
| Chronic Lymphocytic Leukaemia |
4.9% |
| Renal Cell Carcinoma |
4.9% |
| Bone Density Decreased |
4.1% |
| Convulsion |
4.1% |
| Hypertension |
4.1% |
| Osteoporosis |
3.0% |
| Haemorrhoids |
2.6% |
| Bone Pain |
2.3% |
| Pancreatic Carcinoma |
2.3% |
| Renal Transplant |
2.3% |
| Heart Transplant |
1.9% |
| Prostate Cancer |
1.9% |
| Rheumatoid Arthritis |
1.9% |
| Acute Myeloid Leukaemia |
1.5% |
| Drug Use For Unknown Indication |
1.5% |
| Mantle Cell Lymphoma Recurrent |
1.5% |
|
| Weight Decreased |
22.0% |
| Death |
14.0% |
| Lung Infection |
8.0% |
| Bone Pain |
6.0% |
| Pyrexia |
6.0% |
| Renal Cell Carcinoma |
6.0% |
| Blood Creatinine Increased |
4.0% |
| Osteonecrosis |
4.0% |
| Osteonecrosis Of Jaw |
4.0% |
| Pneumonia |
4.0% |
| Sinus Bradycardia |
4.0% |
| Abdominal Pain Upper |
2.0% |
| Acidosis |
2.0% |
| Acute Promyelocytic Leukaemia |
2.0% |
| Arrhythmia |
2.0% |
| Aspartate Aminotransferase Increased |
2.0% |
| Blood Pressure Increased |
2.0% |
| Bursitis |
2.0% |
| Cardiac Disorder |
2.0% |
| Chest Pain |
2.0% |
|
| Interacting |
| Non-small Cell Lung Cancer |
33.3% |
| Pain Management |
33.3% |
| Constipation |
16.7% |
| Prophylaxis Of Nausea And Vomiting |
16.7% |
|
| Epistaxis |
66.7% |
| International Normalised Ratio Increased |
33.3% |
|
